Disease-free survival as surrogate for overall survival in real-world settings for esophageal cancer: an analysis of SEER-Medicare data
Correlations between DFS and OS were meaningful at both individual and treatment effect level. The derived surrogacy equation enables reliable early assessments of OS benefit from the observed DFS benefit for early-stage EC/GEJC treatments in real-world settings.
Authors
- Murat Kurt (ORCID: https://orcid.org/0000-0002-3236-5595)
- Gregory Reardon (ORCID: https://orcid.org/0000-0001-8024-2269)
- Lai K. Leung (ORCID: https://orcid.org/0000-0002-7781-3099)
- I. Kim
- Jaffer A. Ajani (ORCID: https://orcid.org/0000-0001-9946-0629)
- Steve Kanters (ORCID: https://orcid.org/0000-0003-0322-5398)
- Howard S. Frıedman (ORCID: https://orcid.org/0000-0002-3528-5136)
- Prakash Navaratnam
- MM Pourrahmat
- Parul Singh (ORCID: https://orcid.org/0000-0002-0438-3024)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Bristol-Myers Squibb (United States) (US)
- Medidata (United States) (US)
- Keck Graduate Institute (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103934
- Citations
- 4
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.29
Funders
- Bristol-Myers Squibb
- California Department of Public Health
- University of Southern California
- Centers for Disease Control and Prevention
- University of California, San Francisco
- National Cancer Institute